Post-pandemic recovery stocks run out of puff
The Covid-19 vaccines have been successful. Many plays on the global recovery have not done so well.


On 9 November 2020, Pfizer and BioNTech announced that their vaccine for Covid-19 was more effective than almost anybody had hoped, with more than 90% protection against the virus. The news sparked a strong rally in global stockmarkets. Many sectors such as airlines and retail that had been crushed by the closure of the global economy surged on hopes that the world would return to normal, as did broader groupings such as emerging markets and value stocks.
One year on, the Pfizer/BioNTech vaccine and others have met all reasonable expectations. The world has partially reopened, even if a lot of government policies remain clearly irrational and panicky. Yet the outcome for markets hasn’t been as expected. Some much-touted bets have turned out poorly, while some huge returns have come from stocks that were supposed to fall out of favour.
Growth is beating value
We can certainly see plenty of big winners from reopening, especially in retail and leisure. In the UK, bakery chain Greggs and transport operator FirstGroup have both gained over 100%, as has Saga, which offers tours and cruises. But the MSCI World Value index returned 29% in sterling terms over the year, compared to 26% for the MSCI World Growth – a modest difference and one that vanishes if your starting point is one day later. And in recent months, growth has come back more strongly.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sectors such as airlines have done poorly on the whole, up 20% compared with more than 40% for technology. Some of the stay-at-home/work-from-home plays have fallen (eg, online fitness firm Peloton), but many of the tech heavyweights have kept soaring: Microsoft is up 60% and Alphabet up 70%. I’m personally relieved by both of those, because they have helped offset many of the emerging markets in my portfolio: the MSCI Emerging Markets index is up just 5% compared with 27% for the MSCI World.
There are obvious reasons for some of these disappointments. Travel restrictions continue to hold back airlines and are taking longer to remove than expected. Emerging markets have suffered from a slow vaccine roll-out, the loss of tourism and the many economic consequences of the pandemic. Some such as India, Russia and Vietnam have done well, but others such as Brazil are still suffering. Supply-chain bottlenecks, rising labour costs, and higher energy prices play a part, although many of these bring winners as well as losers: energy is up almost 60% over the year.
However, the broader lesson is that investors would rather bet on growth in these uncertain times, no matter how cheap value looks. With plenty of worries for the winter months ahead, there isn’t an obvious catalyst to change that.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
HMRC confirms crypto ETN ISA rules
With crypto ETNs now technically available for UK retail investors, HMRC has confirmed they can be held in an ISA – but there’s a complication
-
Pensioners targeted in fine wine scams – the tactics to watch for
Wine has emerged as the latest lure in investment fraud, with pensioners being specifically targeted by scammers
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?